Actively Recruiting
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
Led by Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe) · Updated on 2026-03-12
1200
Participants Needed
12
Research Sites
64 weeks
Total Duration
On this page
Sponsors
G
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)
Lead Sponsor
L
Life Length SL
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.
CONDITIONS
Official Title
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Person aged 45 years or older at the time of signing the consent form.
- For case group: Diagnosed with small-cell or non-small cell lung cancer confirmed by pathology.
- For case group: No prior oncological treatment before sample collection.
- For high-risk controls (Cohort A): Smoking history of at least 20 pack-years and currently smoking or quit within past 15 years.
- For high-risk controls: No diagnosis or suspicion of lung cancer and chest CT scan within last 12 months with LUNG-RADS score of 3 or lower.
- For low-risk controls (Cohort B): No high risk of lung cancer and no diagnosis or suspicion of lung cancer.
You will not qualify if you...
- History of any malignant tumor except those treated radically and disease-free for at least 5 years.
- Lung cancer patient who has started oncological treatment before sample collection.
- Biopsy, invasive procedure, or minor surgery less than 48 hours ago.
- Major surgery less than 7 days ago.
- Severe chronic kidney disease with glomerular filtration rate below 15 ml/min.
- Severe liver disease classified as Child-Pugh C.
- Active infection or infection treated less than 4 weeks ago.
- Vulnerable populations such as minors, prisoners, pregnant women, or those unable to consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Hospital General Universitario de Elche
Elche, Alicante, Spain
Actively Recruiting
2
Hospital del Mar
Barcelona, Barcelona, Spain
Actively Recruiting
3
Institut Catalá D'Oncologia Badalona (ICO)
Barcelona, Barcelona, Spain
Actively Recruiting
4
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Actively Recruiting
5
Clínica Universidad de Navarra
Madrid, Madrid, Spain
Actively Recruiting
6
HM Sanchinarro/CIOCC
Madrid, Madrid, Spain
Actively Recruiting
7
Hospital Universitario 12 Octubre
Madrid, Madrid, Spain
Actively Recruiting
8
Hospital Universitario Clínico San Carlos
Madrid, Madrid, Spain
Actively Recruiting
9
Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, Spain
Actively Recruiting
10
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Actively Recruiting
11
Complejo Hospitalario de Toledo
Toledo, Toledo, Spain
Actively Recruiting
12
Hospital Universitari I Politècnic La Fe
Valencia, Valencia, Spain
Actively Recruiting
Research Team
A
Antonio Cubillo, MD
CONTACT
P
Paloma Peinado, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here